The landmark decision to rename Polycystic Ovarian Syndrom (PCOS) to Polyendocrine Metabolic Syndrome (PMOS) reflects a push to better represent the realities of the condition. Broadening the name from PCOS – a name that emphasizes the involvement and importance of ovarian cysts in the condition, to PMOS, which underscores the whole-body reality of the syndrome, aims to both better represent the condition to the public, but also emphasize the multi-system implications within a clinical context – that is, for patients and care providers. The shift in name from polycystic ovarian syndrome (PCOS) to polyendocrine metabolic syndrome (PMOS) is a huge change, and one that certainly better represents the realities of the condition that affects over 170 million people worldwide. We’re hopeful that this change in language will help to support an improvement in clinical care and support offered globally as well.